IGHA1 and IgA glomerulonephritis: The failure of rituximab and the clinical success of Nefecon in IgA nephropathy suggests a relationship between rituximab-resistant mucosal B cells and the continued production of IgA1, and supports the significance of mucosal immunity in IgA nephropathy.